Immuneering
NEWS
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
It’s been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
More biopharma companies race toward the Nasdaq this week, while a few rake in cash via private funding rounds.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
Ben Zeskind, chief executive officer of Immuneering, spoke with BioSpace following the annual J.P. Morgan Healthcare conference in San Francisco.
JOBS
IN THE PRESS